O'Riordan T G, Smaldone G C
Division of Pulmonary/Critical Care Medicine, State University of New York at Stony Brook.
Chest. 1994 Feb;105(2):396-401. doi: 10.1378/chest.105.2.396.
In most patients, the deposition of aerosolized pentamidine (AP) is less in the apex of the lung relative to the base. As the apex of the lung is relatively less ventilated than the base, it is possible that reduced regional ventilation may explain the inhomogeneity in regional drug deposition. The purpose of this study was to measure the relationship between regional deposition of AP and regional ventilation, and the influence of particle size and airway caliber on this relationship. Ten subjects with HIV infection who were receiving prophylaxis with AP were recruited. Using krypton (81mKr), we measured regional ventilation during treatment with AP, labeled with 99mTc. Two nebulizers were used (Respirgard II and Fisoneb) that produced particles of different size. In addition, patients were studied with and without a bronchodilator because changes in airway geometry can affect sites of particle deposition. There was no significant correlation between regional ventilation and regional particle deposition (r = 0.00, linear regression). Particle deposition in the upper lobes relative to the lower lobes was less than would be predicted by regional ventilation, by a ratio of 0.84 +/- 0.03 (mean +/- SE). Using two-way analysis of variance (ANOVA), the upper to lower zone deposition pattern was not affected by either nebulizer or by the use of albuterol. The Fisoneb had significantly more central deposition relative to the jet nebulizer (mean +/- SE, skC/P: Fisoneb 1.3 +/- 0.1, Respirgard 1.1 +/- 0.1, p = 0.005, two-way ANOVA). The use of a bronchodilator did not significantly affect the central/peripheral deposition pattern. We conclude that differences in deposition between upper and lower lung regions are not accounted for simply by differences in regional ventilation in patients undergoing prophylaxis with AP. In assessing the cause of regional inhomogeneities of pharmaceutical aerosol deposition (and in devising strategies to achieve more uniform distribution), regional ventilation should be measured directly rather than be inferred from the deposition pattern of the aerosol.
在大多数患者中,雾化喷他脒(AP)在肺尖的沉积相对于肺底较少。由于肺尖的通气相对比肺底少,区域通气减少可能解释了区域药物沉积的不均匀性。本研究的目的是测量AP的区域沉积与区域通气之间的关系,以及粒径和气道管径对这种关系的影响。招募了10名接受AP预防治疗的HIV感染受试者。使用氪(81mKr),我们在使用99mTc标记的AP治疗期间测量区域通气。使用了两种产生不同大小颗粒的雾化器(Respirgard II和Fisoneb)。此外,对患者在使用和不使用支气管扩张剂的情况下进行研究,因为气道几何形状的变化会影响颗粒沉积部位。区域通气与区域颗粒沉积之间无显著相关性(r = 0.00,线性回归)。上叶相对于下叶的颗粒沉积比区域通气预测的要少,比例为0.84±0.03(平均值±标准误)。使用双向方差分析(ANOVA),上下区沉积模式不受雾化器或沙丁胺醇使用的影响。相对于喷射雾化器,Fisoneb的中心沉积明显更多(平均值±标准误,skC/P:Fisoneb 1.3±0.1,Respirgard 1.1±0.1,p = 0.005,双向ANOVA)。使用支气管扩张剂对中心/外周沉积模式无显著影响。我们得出结论,在接受AP预防治疗的患者中,肺上下区域沉积的差异不能简单地用区域通气差异来解释。在评估药物气溶胶沉积区域不均匀性的原因(以及制定实现更均匀分布的策略时),应直接测量区域通气,而不是从气溶胶的沉积模式推断。